Skip to main content

AI Bias Analysis

4 models · Takes ~15 seconds

MarketWatch

‘King Keytruda’s reign continues.’ Investors aren’t wowed by a promising new lung cancer drug.

‘King Keytruda’s reign continues.’ Investors aren’t wowed by a promising new lung cancer drug.
ShareXFacebook

The highly anticipated study found that ivonescimab reduced the risk of death by 34% compared with another drug

M

Source

MarketWatch

Read full article at MarketWatch

Opens original article in a new tab

Advertisement

Related Economy Stories

Advertisement